Clinical trials
catalyst calendar across sponsors →Studies where AKTS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 8 tracked-famous managers (SOROS FUND MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, POLEN CAPITAL MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, Squarepoint Ops LLC, +3 more) · FINRA short interest 12.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117Part 1: Number of Patients with Dose-Limiting ToxicitiesOpen-label · Treatment | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer | 150 | Dec 2027 | ≤ 498 d | 2026-07-10 |
| A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerNCT07581184Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519Open-label · Treatment | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) | Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3 | 138 | Dec 2027 | ≤ 498 d | 2026-07-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19